Ensysce Biosciences Inc. to Present at 11th Annual Pain and Migraine Therapeutic Summit in San Diego, CA on September 27, 2017
Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences, Inc. has been invited to present at the 11th Annual Pain & Migraine Therapeutics Summit to be held September 27 and 28 in San Diego CA. Dr. Kirkpatrick will present “Two-stage, GI Enzyme Activated Opioid Prodrugs and Combination Products for Abuse Prevention and Overdose Protection” at 3:15 PM PDT on Wednesday, September 27th. She will be discussing the recently completed clinical trial which demonstrated the safety and efficient oral activation of BIO-MDTM oxycodone prodrug, PF614. Ensysce’s BIO-MDTM prodrug platform provides abuse deterrence for inhalation, injection and chewing of single agent products. The Human Abuse Liability approach to development will be reviewed along with the Multi-Pill Abuse Resistant (MPARTM) technology overdose protection that can be applied to this pipeline of products.
About Ensysce Biosciences:
Ensysce Biosciences, San Diego CA, is an integrated drug delivery company for both small and large molecules. The BIO-MDTM prodrug abuse deterrent and MPAR™ overdose resistant pain platforms of Ensysce eliminate the ability to abuse opioid products by the non-oral route, something that is the fastest growing drug problem in the US and that leads to billions in healthcare costs annually. The technology, with a worldwide intellectual patent protection, has been successfully validated in Phase 1 studies of the BIO-MDTM hydromorphone prodrug, PF329 and oxycodone prodrug, PF614.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925005255/en/
Ensysce Biosciences Inc.
Dr. Lynn Kirkpatrick, 858-242-1553
